Jill P Smith1, David C Whitcomb, Gail L Matters, Randall E Brand, Jiangang Liao, Yu-Jing Huang, Marsha L Frazier. 1. From the *Department of Medicine, Georgetown University, Washington, DC; †Department of Medicine, Pennsylvania State University, College of Medicine, Hershey; ‡Department of Medicine, University of Pittsburgh; §University of Pittsburgh Medical Center, Pittsburgh; Departments of ∥Biochemistry and Molecular Biology, and ¶Public Health Sciences, Pennsylvania State University, College of Medicine, Hershey, PA; and #Department of Epidemiology, University of Texas at MD Anderson Cancer Center, Houston, TX.
Abstract
OBJECTIVE: Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer through the CCK-B receptor (CCK-BR). A splice variant of the CCK-BR that results from a single nucleotide polymorphism (SNP) has been identified. Because the splice variant receptor has an extended third intracellular loop, an area involved in cell signaling and growth, we hypothesized that this genetic variant could contribute to the poor prognosis and short survival of this malignancy. METHODS: DNA from 931 patients with pancreatic cancer was evaluated for the SNP (C > A; rs1800843) in the CCK-BR gene. For statistical analysis, the Fisher exact test was used to compare the genotype and allele frequency between the cancer cohort and normal controls and the dependence of genotype on factors, such as stage of disease and age, was analyzed using Cox proportional hazards models. RESULTS: Compared to the normal cohort, the frequency of the A-allele in pancreatic cancer subjects was increased (P = 0.01123; odds ratio, 2.283). Even after adjustment for stage of disease, survival of subjects with the minor allele was significantly shorter than those with the wild-genotype (hazard ratio, 1.83; P = 3.11 × 10(-11)). CONCLUSIONS: The CCK-BR SNP predicts survival and should be studied as a candidate genetic biomarker for those at risk of pancreatic cancer.
OBJECTIVE:Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer through the CCK-B receptor (CCK-BR). A splice variant of the CCK-BR that results from a single nucleotide polymorphism (SNP) has been identified. Because the splice variant receptor has an extended third intracellular loop, an area involved in cell signaling and growth, we hypothesized that this genetic variant could contribute to the poor prognosis and short survival of this malignancy. METHODS: DNA from 931 patients with pancreatic cancer was evaluated for the SNP (C > A; rs1800843) in the CCK-BR gene. For statistical analysis, the Fisher exact test was used to compare the genotype and allele frequency between the cancer cohort and normal controls and the dependence of genotype on factors, such as stage of disease and age, was analyzed using Cox proportional hazards models. RESULTS: Compared to the normal cohort, the frequency of the A-allele in pancreatic cancer subjects was increased (P = 0.01123; odds ratio, 2.283). Even after adjustment for stage of disease, survival of subjects with the minor allele was significantly shorter than those with the wild-genotype (hazard ratio, 1.83; P = 3.11 × 10(-11)). CONCLUSIONS: The CCK-BR SNP predicts survival and should be studied as a candidate genetic biomarker for those at risk of pancreatic cancer.
Authors: Gail L Matters; Christopher McGovern; John F Harms; Kevin Markovic; Krystal Anson; Calpurnia Jayakumar; Melissa Martenis; Christina Awad; Jill P Smith Journal: Int J Oncol Date: 2010-12-24 Impact factor: 5.650
Authors: Jill P Smith; Michael F Verderame; Patricia McLaughlin; Melissa Martenis; Elizabeth Ballard; Ian S Zagon Journal: Int J Mol Med Date: 2002-12 Impact factor: 4.101
Authors: Morgan O'Hayre; José Vázquez-Prado; Irina Kufareva; Eric W Stawiski; Tracy M Handel; Somasekar Seshagiri; J Silvio Gutkind Journal: Nat Rev Cancer Date: 2013-05-03 Impact factor: 60.716
Authors: Anita Balázs; Balázs Csaba Németh; Balázs Ördög; Eszter Hegyi; István Hritz; László Czakó; József Czimmer; Szilárd Gódi; Adrienn Csiszkó; Zoltán Rakonczay; Andrea Párniczky; Ferenc Izbéki; Adrienn Halász; Zsuzsanna Kahán; Péter Hegyi; Miklós Sahin-Tóth Journal: Pancreas Date: 2016-04 Impact factor: 3.327
Authors: Taíssa Maíra Thomaz Araújo; Williams Fernandes Barra; André Salim Khayat; Paulo Pimentel de Assumpção Journal: Chin J Cancer Res Date: 2017-04 Impact factor: 5.087
Authors: Jelal Alsubai; Gail L Matters; Christopher O McGovern; Jiangang Liao; Evan L Gilius; Jill P Smith Journal: Clin Transl Gastroenterol Date: 2016-01-07 Impact factor: 4.488